Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

阿尔茨海默病患者血清Sirtuin-1、HMGB1-TLR4、NF-KB和IL-6水平:神经炎症通路与痴呆严重程度的关系

卷 19, 期 12, 2022

发表于: 05 January, 2023

页: [841 - 848] 页: 8

弟呕挨: 10.2174/1567205020666221226140721

价格: $65

摘要

阿尔茨海默病(AD)影响着全球的老龄化人口，是一种进行性神经退行性疾病，需要标记物或工具来准确、容易地诊断和监测这一过程。 目的：在这项研究中，研究了根据NINCS-ADRA标准诊断为AD患者的血清Sirtuin-1(SIRT-1)、高迁移率基团箱1(HMGB1)、toll样受体-4 (TLR4)、核因子Kappa B (NF-kB)、白细胞介素-6 (IL-6)、淀粉样βeta-42 (Aβ- 42)和p-tau181水平。我们研究了导致进行性神经元丧失的炎症通路，并强调了它们与体循环中痴呆严重程度的可能关系。 方法：年龄超过60岁的患者根据其标准迷你智力测试结果、MRI和/或氟脱氧葡萄糖正电子发射断层扫描(Fludeoxyglucose positron emission tomography)，或根据其CT结果进行分组，作为对照组20例;广告n: 32;血管性痴呆(VD) n:17;AD + vd;N = 21。评估全血计数、葡萄糖、维生素B12、叶酸、酶、尿素、肌酐、电解质、胆红素和甲状腺功能测试。ELISA法检测血清SIRT1、HMGB1、TLR4、NF-kB、IL-6、Aβ-42、p-tau181水平。 结果：痴呆组的血清Aβ-42、SIRT1、HMGB1和IL-6水平显著高于对照组(p< 0.001、p< 0.01、p< 0.001和p< 0.001)， TLR4水平显著低于对照组(p< 0.001)。痴呆组和对照组血清NF-kB和p-tau181水平无显著差异。 结论：我们的研究结果表明，在AD和VD中，Aβ42、SIRT 1、HMGB1和TLR4通路的水平被改变。SIRT 1活性在痴呆症发展的炎症途径中起着重要作用，特别是在AD中。

关键词: Sirtuin-1、HMGB1、TLR4、NF- kB、il - 6、A -β,p-tau181、痴呆。

« Previous
[1]
van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci 2020; 21(1): 21-35.
[http://dx.doi.org/10.1038/s41583-019-0240-3] [PMID: 31780819]
[2]
Castellani RJ, Peclovits A, Perry G. Neuropathology of Alzheimer’s disease. In: pathobiology of human disease. Elsevier 2014; pp. 2014-.
[http://dx.doi.org/10.1016/B978-0-12-386456-7.04604-9]
[3]
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020; 19(5): 422-33.
[http://dx.doi.org/10.1016/S1474-4422(20)30071-5] [PMID: 32333900]
[4]
Lalla R, Donmez G. The role of sirtuins in Alzheimer’s disease. Front Aging Neurosci 2013; 5: 16.
[http://dx.doi.org/10.3389/fnagi.2013.00016] [PMID: 23576985]
[5]
Balaiya S, Abu-Amero KK, Kondkar AA, Chalam KV. Sirtuins expression and their role in retinal diseases. Oxid Med Cell Longev 2017; 2017: 3187594.
[http://dx.doi.org/10.1155/2017/3187594] [PMID: 28197299]
[6]
Kilic U, Elibol B, Uysal O, et al. Specific alterations in the circulating levels of the SIRT1, TLR4, and IL7 proteins in patients with dementia. Exp Gerontol 2018; 111: 203-9.
[http://dx.doi.org/10.1016/j.exger.2018.07.018] [PMID: 30071285]
[7]
Paudel YN, Shaikh MF, Chakraborti A, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci 2018; 12: 628.
[http://dx.doi.org/10.3389/fnins.2018.00628] [PMID: 30271319]
[8]
Kiiski H, Långsjö J, Tenhunen J, et al. Time-courses of plasma IL-6 and HMGB-1 reflect initial severity of clinical presentation but do not predict poor neurologic outcome following subarachnoid hemorrhage. eNeurologicalSci 2017; 6: 55-62.
[http://dx.doi.org/10.1016/j.ensci.2016.11.010] [PMID: 29260012]
[9]
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol 2007; 6(8): 734-46.
[http://dx.doi.org/10.1016/S1474-4422(07)70178-3] [PMID: 17616482]
[10]
Singh V, Ubaid S. Role of Silent Information Regulator 1 (SIRT1) in regulating oxidative stress and inflammation. Inflammation 2020; 43(5): 1589-98.
[http://dx.doi.org/10.1007/s10753-020-01242-9] [PMID: 32410071]
[11]
Kumar R, Chaterjee P, Sharma PK, et al. Sirtuin1: A promising serum protein marker for early detection of Alzheimer’s disease. PLoS One 2013; 8(4): e61560.
[http://dx.doi.org/10.1371/journal.pone.0061560] [PMID: 23613875]
[12]
Pradhan R, Singh AK, Kumar P, et al. Blood circulatory level of seven sirtuins in alzheimer’s disease: Potent biomarker based on translational research. Mol Neurobiol 2022; 59(3): 1440-51.
[http://dx.doi.org/10.1007/s12035-021-02671-9] [PMID: 34993847]
[13]
Sinem F, Dildar K, Gökhan E, Melda B, Orhan Y, Filiz M. The serum protein and lipid oxidation marker levels in Alzheimer’s disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res 2010; 7(5): 463-9.
[http://dx.doi.org/10.2174/156720510791383822] [PMID: 20043811]
[14]
Tang Y, Zhao X, Antoine D, et al. Regulation of posttranslational modifications of HMGB1 during immune responses. Antioxid Redox Signal 2016; 24(12): 620-34.
[http://dx.doi.org/10.1089/ars.2015.6409] [PMID: 26715031]
[15]
Festoff BW, Sajja RK, van Dreden P, Cucullo L. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflammation 2016; 13(1): 194.
[http://dx.doi.org/10.1186/s12974-016-0670-z] [PMID: 27553758]
[16]
Bowie A, O’Neill LAJ. The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67(4): 508-14.
[http://dx.doi.org/10.1002/jlb.67.4.508] [PMID: 10770283]
[17]
Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM. Quantification of Alzheimer pathology in aging and dementia: Age-related accumulation of amyloid-β(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006; 32(2): 103-8.
[18]
Mayeux R, Honig LS, Tang MX, et al. Plasma A 40 and A 42 and Alzheimer’s disease: Relation to age, mortality, and risk. Neurology 2003; 61(9): 1185-90.
[http://dx.doi.org/10.1212/01.WNL.0000091890.32140.8F] [PMID: 14610118]
[19]
Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008; 104(2): 524-33.
[http://dx.doi.org/10.1111/j.1471-4159.2007.05001.x] [PMID: 17986235]
[20]
Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in A uptake and clearance. Brain 2006; 129(11): 3006-19.
[http://dx.doi.org/10.1093/brain/awl249] [PMID: 16984903]
[21]
Belkhelfa M, Beder N, Mouhoub D, et al. The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. J Neuroimmunol 2018; 320: 48-57.
[http://dx.doi.org/10.1016/j.jneuroim.2018.04.004] [PMID: 29759140]
[22]
Terai K, Matsuo A, McGeer PL. Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer’s disease. Brain Res 1996; 735(1): 159-68.
[http://dx.doi.org/10.1016/0006-8993(96)00310-1] [PMID: 8905182]
[23]
Kaltschmidt B, Ndiaye D, Korte M, et al. NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006; 26(8): 2936-46.
[http://dx.doi.org/10.1128/MCB.26.8.2936-2946.2006] [PMID: 16581769]
[24]
Lian H, Yang L, Cole A, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron 2015; 85(1): 101-15.
[http://dx.doi.org/10.1016/j.neuron.2014.11.018] [PMID: 25533482]
[25]
García-García VA, Alameda JP, Page A, Casanova ML. Role of nf-κb in aging and age-related diseases: Lessons from genetically modified mouse models. Cells 2021; 10(8): 1906.
[http://dx.doi.org/10.3390/cells10081906] [PMID: 34440675]
[26]
Yang Y, Han C, Guo L, Guan Q. High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson’s disease and the relationship of pathological staging. Brain Behav 2018; 8(4): e00948.
[http://dx.doi.org/10.1002/brb3.948] [PMID: 29670828]
[27]
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology 2021; 190: 108352.
[http://dx.doi.org/10.1016/j.neuropharm.2020.108352] [PMID: 33035532]
[28]
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69 (Suppl. 1): S4-9.
[http://dx.doi.org/10.1093/gerona/glu057] [PMID: 24833586]
[29]
Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012; 8(9): 1254-66.
[http://dx.doi.org/10.7150/ijbs.4679] [PMID: 23136554]
[30]
Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 2010; 68(10): 930-41.
[http://dx.doi.org/10.1016/j.biopsych.2010.06.012] [PMID: 20692646]
[31]
Bozluolcay M, Andican G, Fırtına S, Erkol G, Konukoglu D. Inflammatory hypothesis as a link between Alzheimer’s disease and diabetes mellitus. Geriatr Gerontol Int 2016; 16(10): 1161-6.
[http://dx.doi.org/10.1111/ggi.12602] [PMID: 26337250]
[32]
Uslu S, Eken Z, Demet A. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementia. Neurochem Res 2012; 37(7): 1554-9.
[33]
Vishnu VY, Modi M, Garg VK, Mohanty M, Goyal MK, Lal V. Role of inflammatory and hemostatic biomarkers in Alzheimer’s and vascular dementia – A pilot study from a tertiary center in Northern India. Asian J Psychiatr 2016; 2017(29): 59-62.
[34]
Karadaş Ö, Koç G, Özön AÖ, Öztürk B, Konukoğlu D. Biomarkers of Alzheimer’s disease and vascular dementia simultaneously sampled from serum and cerebrospinal fluid. Turk Geriatri Derg 2017; 20(1): 1-7.
[35]
Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16(3): 136-44.
[http://dx.doi.org/10.1159/000071001] [PMID: 12826739]
[36]
Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer’s disease and vascular dementia. Int J Neurosci 2008; 118(12): 1659-72.
[http://dx.doi.org/10.1080/00207450701392068] [PMID: 18937113]
[37]
Tang L, Chen Q, Meng Z, et al. Suppression of sirtuin-1 increases IL-6 expression by activation of the akt pathway during allergic asthma. Cell Physiol Biochem 2017; 43(5): 1950-60.
[http://dx.doi.org/10.1159/000484119] [PMID: 29055943]
[38]
Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol 2007; 66(12): 1136-46.
[http://dx.doi.org/10.1097/nen.0b013e31815c5efb] [PMID: 18090922]
[39]
Tsai CL, Liang CS, Lee JT, et al. Associations between plasma biomarkers and cognition in patients with Alzheimer’s disease and amnestic mild cognitive impairment: A cross- sectional and longitudinal study. J Clin Med 2019; 8(11): 1893.
[http://dx.doi.org/10.3390/jcm8111893] [PMID: 31698867]
[40]
Chen SD, Huang YY, Shen XN, et al. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease. Transl Psychiatry 2021; 11(1): 356.
[http://dx.doi.org/10.1038/s41398-021-01476-7] [PMID: 34120152]

Rights & Permissions Print Cite
Article Metrics
36
3
© 2024 Bentham Science Publishers | Privacy Policy